Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,547.55 +666.58 (+1.06%) CMC Crypto 200
1,390.17 -6.37 (-0.46%)
Kineta, Inc. (KA)
After hours:
| Previous close | 0.6248 |
| Open | 0.6035 |
| Bid | 0.5761 x 500 |
| Ask | 0.6202 x 500 |
| Day's range | 0.5694 - 0.6167 |
| 52-week range | 0.3340 - 5.3900 |
| Volume | |
| Avg. volume | 374,782 |
| Market cap | 6.687M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2800 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.50 |
GlobeNewswireKineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of CRS-associated cytokines observed at any dose level Cleared fifth of six monotherapy cohorts and second of four combination cohorts SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the deve
- GlobeNewswire
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxicities observed at any dose level in the VISTA-101 trial Cleared fifth of six monotherapy cohorts and second of four combination cohorts in the VISTA-101 trial Kineta is actively exploring strategic alternatives to maximize value for all stakeholders SEATTLE, March 21, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clini
- GlobeNewswire
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsNo dose limiting toxicities observed at any dose levelCleared fifth of six monotherapy cohorts and second of four combination cohortsKineta is actively exploring strategic alternatives to maximize value for all stakeholders SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immu
